Migraine Prophylaxis: Rimegepant vs Placebo, Erenumab, and Galcanezumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Headache
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Matching-Adjusted Indirect Comparisons of Oral Rimegepant Versus Placebo, Erenumab, and Galcanezumab Examining Monthly Migraine Days and Health-Related Quality of Life in the Treatment of Migraine
Headache 2021 May 22;[EPub Ahead of Print], E Popoff, K Johnston, R Croop, A Thiry, L Harris, L Powell, V Coric, G L'Italien, J MorenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.